Valuation: Akeso, Inc.

Capitalization 10TCr 12TCr 1.49TCr 1.28TCr 1.19TCr 1.11TCr 2.07TCr 1,34300Cr 2.22TCr 14TCr 5.37TCr 64TCr 5.59TCr 5.47TCr 2,35500Cr P/E ratio 2025 *
-510x
P/E ratio 2026 * 131x
Enterprise value 10TCr 11TCr 1.44TCr 1.24TCr 1.15TCr 1.07TCr 2TCr 1,30000Cr 2.15TCr 13TCr 5.2TCr 62TCr 5.41TCr 5.3TCr 2,28100Cr EV / Sales 2025 *
30x
EV / Sales 2026 * 18.4x
Free-Float
74.46%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
12/12 Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab CI
11/12 Akeso, Inc. Announces Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented atESMO IO 2025 CI
09/12 Akeso, Inc. Announces Phase II Data of Cadonilimab Regimen as Neoadjuvant Therapy for Resectable Gastric Cancer Presented at ESMO Asia Congress CI
09/12 Akeso, Inc. Announces Significant Improvement in Quality of Life Reported in Updated HARMONi-6 Data for Ivonescimab at ESMO Asia CI
17/11 Akeso, Inc.'s Bispecific Antibody Targeting Aß and BBB-Expressed Receptor Approved for Alzheimer's Disease Clinical Trials in China CI
10/11 Akeso announces first patient dosed in Phase I trial of personalized mRNA vaccine AK154 as monotherapy or in combination with Cadonilimab or Ivonescimab RE
10/11 Akeso Announces First Patient Dosed in Phase I Trial of Personalized mRNA Vaccine AK154 as Monotherapy or in Combination with Cadonilimab or Ivonescimab for Adjuvant Treatment of Pancreatic Cancer CI
07/11 Akeso, Inc. Unveils Promising Preclinical Data for IL-1RAP Targeting Antibody At SITC 2025 CI
07/11 Akeso Announces Final OS Analysis Results Of Ivonescimab HARMONi-A Study At SITC 2025 CI
03/11 Akeso's Ivonescimab Secures Fourth Breakthrough Therapy Designation in China for First-Line Treatment of Triple-Negative Breast Cancer CI
31/25/31 Summit Therapeutics Inc. Announces Results from the Phase III Harmoni-A Trial, Conducted in China and Sponsored by Akeso, Inc CI
21/25/21 Akeso's Ivonescimab Shows Strong Phase 3 Results in Lung Cancer Trial MT
19/25/19 Akeso Announces Results of the Registrational Phase III Clinical Study Evaluating Ivonescimab (PD-1/VEGF Bispecific Antibody) CI
More news
1 day-3.65%
1 week+3.76%
Current month+7.52%
1 month-2.41%
3 months-4.03%
6 months+2.79%
Current year+7.52%
More quotes
1 week 116
Extreme 116
130.5
1 month 108
Extreme 108
130.5
Current year 111
Extreme 111
130.5
1 year 54
Extreme 54
179
3 years 26.45
Extreme 26.45
179
5 years 11.5
Extreme 11.5
179
10 years 11.5
Extreme 11.5
179
More quotes
Manager TitleAgeSince
Corporate Officer/Principal 50 16/11/2019
Corporate Officer/Principal 57 16/11/2019
Chief Tech/Sci/R&D Officer 58 16/11/2019
Director TitleAgeSince
Chairman 59 19/03/2012
Director/Board Member 58 16/11/2019
Director/Board Member 57 16/11/2019
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-3.57%+3.76%+119.31%+164.42% 1.49TCr
-3.14%-1.73%+3.87%+82.75% 4.8TCr
-0.40%+4.35%+84.93%+8.53% 4.2TCr
-4.69%-4.27%+157.04%+768.57% 3.58TCr
+2.33%+5.50%-16.83%-31.61% 2.56TCr
-0.92%+7.56%+38.32%-21.04% 2.08TCr
+5.16%+17.84%+133.73%-42.12% 1.99TCr
-13.41%-2.29%-4.54%+323.88% 1.31TCr
-3.15%+9.81%+181.88% - 1.46TCr
+0.05%+3.92%+22.32%+163.99% 1.19TCr
Average -0.87%+4.42%+72.00%+157.49% 2.47TCr
Weighted average by Cap. -1.38%+2.97%+69.09%+165.43%
See all sector performances

Financials

2025 *2026 *
Net sales 335.32Cr 374.91Cr 48Cr 41Cr 38Cr 36Cr 67Cr 4.33TCr 72Cr 441.13Cr 173.4Cr 2.07TCr 180.34Cr 176.64Cr 7.6TCr 538.96Cr 602.6Cr 77Cr 66Cr 62Cr 57Cr 107.22Cr 6.97TCr 115Cr 709.03Cr 278.7Cr 3.33TCr 289.86Cr 283.91Cr 12TCr
Net income -19Cr -21Cr -2.68Cr -2.29Cr -2.13Cr -1.99Cr -3.71Cr -241.31Cr -3.98Cr -25Cr -9.65Cr -115.45Cr -10Cr -9.83Cr -423.29Cr 79Cr 89Cr 11Cr 9.74Cr 9.05Cr 8.44Cr 16Cr 1.02TCr 17Cr 104.31Cr 41Cr 490.27Cr 43Cr 42Cr 1.8TCr
Net Debt -330.22Cr -369.21Cr -47Cr -41Cr -38Cr -35Cr -66Cr -4.27TCr -70Cr -434.41Cr -170.76Cr -2.04TCr -177.59Cr -173.95Cr -7.49TCr -478.49Cr -534.99Cr -69Cr -59Cr -55Cr -51Cr -95Cr -6.18TCr -102.1Cr -629.47Cr -247.43Cr -2.96TCr -257.34Cr -252.06Cr -11TCr
More financial data * Estimated data
Logo Akeso, Inc.
Akeso Inc is an investment holding company mainly engaged in the research and development, production and commercialization of biopharmaceutical products. The Company is committed to the research, development, manufacturing and commercialization of innovative antibody drugs that are affordable to patients worldwide. The Company's products mainly include cadonilimab (PD-1/CTLA-4), Ivonescimab (AK112, PD-1/VEGF), ANNIKO (penpulimab, PD-1), Ebronucimab (AK102, PCSK9) and ebdarokimab (AK101, IL-12/IL-23). The Company's products are principally used to treat tumors, autoimmune diseases, metabolic diseases, as well as neurodegenerative diseases. The Company principally conducts its businesses in Mainland China, the United States and other markets.
Employees
3,529
More about the company
Date Price Change Volume
13/26/13 121.80 $ -3.41% 96,21,398
12/26/12 126.10 $ -1.18% 71,69,029
09/26/09 127.60 $ -0.47% 46,44,895
08/26/08 128.20 $ -0.77% 48,41,419
07/26/07 129.20 $ +7.31% 1,14,29,410

Delayed Quote Hong Kong S.E., January 13, 2026 at 11:05 am IST

More quotes
Trader
Investor
Global
Quality
ESG MSCI
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
112.78CNY
Average target price
154.69CNY
Spread / Average Target
+37.16%
Consensus

Quarterly revenue - Rate of surprise